Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Says Au Revoir To Viehbacher, But Is It Committing A Faux Pas?

Executive Summary

The French pharma's abrupt dismissal of its CEO, citing execution problems with its best-selling drug and issues with management style, has investors wondering whether Chris Viehbacher should have gotten the benefit of the doubt from the company’s board, given his impressive track record.

You may also be interested in...



Sanofi’s Revamped Business Structure Includes Three New Pharma Units

The French pharma said it will operate with five global business units beginning in January 2016: General Medicines & Emerging Markets, Specialty Care, Diabetes & Cardiovascular, Sanofi Pasteur and Merial.

Sanofi’s Revamped Business Structure Includes Three New Pharma Units

The French pharma said it will operate with five global business units beginning in January 2016: General Medicines & Emerging Markets, Specialty Care, Diabetes & Cardiovascular, Sanofi Pasteur and Merial.

Sanofi’s Revamped Business Structure Includes Three New Pharma Units

The French pharma said it will operate with five global business units beginning in January 2016: General Medicines & Emerging Markets, Specialty Care, Diabetes & Cardiovascular, Sanofi Pasteur and Merial.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS056450

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel